IDH1 and acute myeloid leukemia: Ivosidenib was also recently approved as first-line of treatment for newly diagnosed AML in patients over 75 years old [208] while preliminary results from phase III clinical trials seem to prove its clinical activity also in IDH1 mutated cholangiocarcinoma [209].